Directory
>
David Schenkein
David Schenkein
Senior Vice President, Clinical Research | Regeneron
Massachusetts, Boston, United States
David Schenkein
Summary
Dr. David Schenkein is a distinguished hematologist and general partner at GV, where he co-heads the life science investment team. He has dedicated over 30 years to the fields of hematology and oncology, significantly impacting cancer research and treatment. Previously, he served as CEO of Agios Pharmaceuticals, where he remains on the board, and held a senior vice president position at Genentech, contributing to the approval of several oncology drugs. Dr. Schenkein also has experience in academic medicine, serving as an adjunct attending physician at Tufts Medical Center and a clinical professor at Stanford University. His leadership extends to board positions at bluebird bio and Denali Therapeutics. With a solid educational background in chemistry and medicine, Dr. Schenkein combines scientific expertise with strategic investment acumen in the life sciences sector. He is known for his commitment to innovative cancer therapies and improving patient outcomes.
David Schenkein
Work Experience
Board Member at
Regeneron
September 2023 - Present
David Schenkein
Education
State University of New York Upstate Medical University, Doctor of Medicine (M.D.)
January 1979 - January 1983
Wesleyan University, Bachelor of Arts (B.A.), Chemistry
January 1975 - January 1979
Frequently Asked Questions about David Schenkein
What is David Schenkein email address?
David Schenkein's primary email address is *********@agios.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does David Schenkein work for?
David Schenkein is a Senior Vice President, Clinical Research at Regeneron.
Where David Schenkein graduated from?
David Schenkein holds a degree in null from State University of New York Upstate Medical University.
How can I directly contact David Schenkein?
To contact David Schenkein directly, you can use the email address *********@agios.com. Complete contact information is available upon registration with Muraena.
Who is David Schenkein?
Dr. David Schenkein is a distinguished hematologist and general partner at GV, where he co-heads the life science investment team. He has dedicated over 30 years to the fields of hematology and oncology, significantly impacting cancer research and treatment. Previously, he served as CEO of Agios Pharmaceuticals, where he remains on the board, and held a senior vice president position at Genentech, contributing to the approval of several oncology drugs. Dr. Schenkein also has experience in academic medicine, serving as an adjunct attending physician at Tufts Medical Center and a clinical professor at Stanford University. His leadership extends to board positions at bluebird bio and Denali Therapeutics. With a solid educational background in chemistry and medicine, Dr. Schenkein combines scientific expertise with strategic investment acumen in the life sciences sector. He is known for his commitment to innovative cancer therapies and improving patient outcomes.
David`s contact details
*********@agios.com
******@regeneron.com
***************@gv.com
Colleagues
Scientist, Product Development
Ixebepilone Medical Lead, Global Medical Affairs
Program Director, Market Research
Associate Researcher
Previous Roles at Novartis
Vice President
Consultant in Rheumatology and Internal Medicine
Tax Senior
Program Director, Licensed Psychologist
Reporter